These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 37667131)

  • 1. Relationship of Histopathologic Parameters and Gene Expression Profiling in Malignant Melanoma.
    Strahan AG; Švagelj I; Jukic D
    Am J Clin Dermatol; 2024 Jan; 25(1):119-126. PubMed ID: 37667131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective validation of the prognostic 31-gene expression profiling test in primary cutaneous melanoma.
    Keller J; Schwartz TL; Lizalek JM; Chang ES; Patel AD; Hurley MY; Hsueh EC
    Cancer Med; 2019 May; 8(5):2205-2212. PubMed ID: 30950242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of high-risk cutaneous melanoma tumors is improved when combining the online American Joint Committee on Cancer Individualized Melanoma Patient Outcome Prediction Tool with a 31-gene expression profile-based classification.
    Ferris LK; Farberg AS; Middlebrook B; Johnson CE; Lassen N; Oelschlager KM; Maetzold DJ; Cook RW; Rigel DS; Gerami P
    J Am Acad Dermatol; 2017 May; 76(5):818-825.e3. PubMed ID: 28110997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimation of Prognosis in Invasive Cutaneous Melanoma: An Independent Study of the Accuracy of a Gene Expression Profile Test.
    Greenhaw BN; Zitelli JA; Brodland DG
    Dermatol Surg; 2018 Dec; 44(12):1494-1500. PubMed ID: 29994951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Level of Evidence Review for a Gene Expression Profile Test for Cutaneous Melanoma.
    Dubin DP; Dinehart SM; Farberg AS
    Am J Clin Dermatol; 2019 Dec; 20(6):763-770. PubMed ID: 31359351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing Genetic Expression Profiles in Melanoma Prognosis.
    Farberg AS; Glazer AM; Winkelmann RR; Rigel DS
    Dermatol Clin; 2017 Oct; 35(4):545-550. PubMed ID: 28886811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of patients at risk of metastasis using a prognostic 31-gene expression profile in subpopulations of melanoma patients with favorable outcomes by standard criteria.
    Gastman BR; Gerami P; Kurley SJ; Cook RW; Leachman S; Vetto JT
    J Am Acad Dermatol; 2019 Jan; 80(1):149-157.e4. PubMed ID: 30081113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-Term Outcomes in a Multicenter, Prospective Cohort Evaluating the Prognostic 31-Gene Expression Profile for Cutaneous Melanoma.
    Hsueh EC; DeBloom JR; Lee JH; Sussman JJ; Covington KR; Caruso HG; Quick AP; Cook RW; Slingluff CL; McMasters KM
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34036233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary dermal melanoma: a unique subtype of melanoma to be distinguished from cutaneous metastatic melanoma: a clinical, histologic, and gene expression-profiling study.
    Sidiropoulos M; Obregon R; Cooper C; Sholl LM; Guitart J; Gerami P
    J Am Acad Dermatol; 2014 Dec; 71(6):1083-92. PubMed ID: 25262174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interim analysis of survival in a prospective, multi-center registry cohort of cutaneous melanoma tested with a prognostic 31-gene expression profile test.
    Hsueh EC; DeBloom JR; Lee J; Sussman JJ; Covington KR; Middlebrook B; Johnson C; Cook RW; Slingluff CL; McMasters KM
    J Hematol Oncol; 2017 Aug; 10(1):152. PubMed ID: 28851416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene expression profiling in melanoma: past results and future potential.
    Knackstedt RW; Knackstedt T; Gastman B
    Future Oncol; 2019 Mar; 15(7):791-800. PubMed ID: 30453756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management Decisions Made by Physician Assistants and Nurse Practitioners in Cutaneous Malignant Melanoma Patients: Impact of a 31-Gene Expression Profile Test.
    Mirsky R; Prado G; Svoboda R; Glazer A; Rigel D
    J Drugs Dermatol; 2018 Nov; 17(11):1220-1223. PubMed ID: 30500144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of a clinicopathological and gene expression profile model to identify patients with cutaneous melanoma where sentinel lymph node biopsy is unnecessary.
    Johansson I; Tempel D; Dwarkasing JT; Rentroia-Pacheco B; Mattsson J; Ny L; Olofsson Bagge R
    Eur J Surg Oncol; 2022 Feb; 48(2):320-325. PubMed ID: 34794843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients.
    Zager JS; Gastman BR; Leachman S; Gonzalez RC; Fleming MD; Ferris LK; Ho J; Miller AR; Cook RW; Covington KR; Meldi-Plasseraud K; Middlebrook B; Kaminester LH; Greisinger A; Estrada SI; Pariser DM; Cranmer LD; Messina JL; Vetto JT; Wayne JD; Delman KA; Lawson DH; Gerami P
    BMC Cancer; 2018 Feb; 18(1):130. PubMed ID: 29402264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved cutaneous melanoma survival stratification through integration of 31-gene expression profile testing with the American Joint Committee on Cancer 8th Edition Staging.
    Wisco OJ; Marson JW; Litchman GH; Brownstone N; Covington KR; Martin BJ; Quick AP; Siegel JJ; Caruso HG; Cook RW; Winkelmann RR; Rigel DS
    Melanoma Res; 2022 Apr; 32(2):98-102. PubMed ID: 35254332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between clinical features, GEP class, and PRAME expression in uveal melanoma.
    Schefler AC; Koca E; Bernicker EH; Correa ZM
    Graefes Arch Clin Exp Ophthalmol; 2019 Jul; 257(7):1541-1545. PubMed ID: 31065847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Attitudes of patients with cutaneous melanoma toward prognostic testing using the 31-gene expression profile test.
    Ahmed K; Siegel JJ; Morgan-Linnell SK; LiPira K
    Cancer Med; 2023 Jan; 12(2):2008-2015. PubMed ID: 35915969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expanded evidence that the 31-gene expression profile test provides clinical utility for melanoma management in a multicenter study.
    Dillon LD; McPhee M; Davidson RS; Quick AP; Martin B; Covington KR; Zolochevska O; Cook RW; Vetto JT; Jarell AD; Fleming MD
    Curr Med Res Opin; 2022 Aug; 38(8):1267-1274. PubMed ID: 35081854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utility of a Model for Predicting the Risk of Sentinel Lymph Node Metastasis in Patients With Cutaneous Melanoma.
    Marchetti MA; Dusza SW; Bartlett EK
    JAMA Dermatol; 2022 Jun; 158(6):680-683. PubMed ID: 35475908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of melanoma: can we use gene expression profiling to help guide treatment and surveillance?
    Zager JS; Hyams DM
    Clin Exp Metastasis; 2024 Aug; 41(4):439-445. PubMed ID: 38064126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.